drugset / Trial / NCT00694980

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

NCT00694980

Phase 1 Completed 48 enrolled Genentech, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized , double-blind, placebo-controlled study of approximately 70 patients with ulcerative colitis.

Timeline

Start
2008-09
Primary completion
2011-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Etrolizumab Monoclonal antibody Intravenous

Indications